Evidence map›Paper›PMID 29238165›Full record

ArticleDrug design, development and therapy2017

Synthesis, characterization, and antimicrobial evaluation of novel 5-benzoyl-

Galal Elgemeie, Farag Altalbawy, Mohammed Alfaidi, Rania Azab, Atef Hassan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Crystal structure of 2-{[5-amino-1-(phenyl-sulfon-yl)-1Acta crystallographica. Section E, Crystallographic communications · 2021
    Article
  3. Crystal structure of ethyl 2-(3-amino-5-oxo-2-tosyl-2,5-di-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2021
    Article
  4. Article
  5. Crystal structure of ethyl 2-(5-amino-1-benzene-sulfonyl-3-oxo-2,3-di-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2020
    Article
  6. Article
  7. Article
  8. Crystal structure of potassium [4-amino-5-(benzo[Acta crystallographica. Section E, Crystallographic communications · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Galal ElgemeieDepartment of Chemistry, Faculty of Science, Helwan University, Helwan.
Farag AltalbawyNational Institute of Laser Enhanced Sciences (NILES), Cairo University, Giza, Egypt.
Mohammed AlfaidiDepartment of Biological Sciences, University College of Duba, Tabuk University, Tabuk.
Rania AzabNational Institute of Laser Enhanced Sciences (NILES), Cairo University, Giza, Egypt.
Atef HassanDepartment of Mycology and Mycotoxins, Animal Health Research Institute, Agriculture Research Center, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The present research describes the synthesis of novel 5-benzoyl-

Indexed as

Anti-Bacterial AgentsAntifungal AgentsCandida albicansDose-Response Relationship, DrugEscherichia coliMicrobial Sensitivity TestsMolecular StructurePyridonesStaphylococcus aureusAnti-Bacterial AgentsAntifungal AgentsPyridones2-benzoyl-3,3-bis(alkylthio)acrylonitriles5-benzoyl-N-substituted-amino-4-alkylsulfanyl-2 pyridones5-benzoyl-N-sulfonylamino-4-alkylsulfanyl-2-pyridonesamino-2-pyridonesantimicrobial activitycyanoaceto-N-phenylsulfonylhydrazideN-cyanoacetohydrazide

Identifiers

PMID29238165
PMCPMC5713685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.